vs
Bioceres Crop Solutions Corp.（BIOX）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
Bioceres Crop Solutions Corp.的季度营收约是READING INTERNATIONAL INC的1.5倍（$77.6M vs $50.3M），READING INTERNATIONAL INC净利率更高（-5.1% vs -9.6%，领先4.5%），READING INTERNATIONAL INC同比增速更快（-14.2% vs -16.8%），过去两年READING INTERNATIONAL INC的营收复合增速更高（5.6% vs -8.4%）
Bioceres Crop Solutions Corp是一家全球农业科技企业，研发并商业化耐旱种子性状、生物肥料、生物农药等可持续作物增产解决方案，服务南美、北美、欧洲及亚太地区的农户，致力于提升作物产量，同时降低农业生产的环境影响。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
BIOX vs RDI — 直观对比
营收规模更大
BIOX
是对方的1.5倍
$50.3M
营收增速更快
RDI
高出2.6%
-16.8%
净利率更高
RDI
高出4.5%
-9.6%
两年增速更快
RDI
近两年复合增速
-8.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $77.6M | $50.3M |
| 净利润 | $-7.4M | $-2.6M |
| 毛利率 | 46.8% | — |
| 营业利润率 | 9.3% | -1.9% |
| 净利率 | -9.6% | -5.1% |
| 营收同比 | -16.8% | -14.2% |
| 净利润同比 | -20.2% | -14.5% |
| 每股收益（稀释后） | $-0.12 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOXRDI
| Q4 25 | — | $50.3M | ||
| Q3 25 | $77.6M | $52.2M | ||
| Q2 25 | — | $60.4M | ||
| Q1 25 | $60.6M | $40.2M | ||
| Q4 24 | $98.8M | $58.6M | ||
| Q3 24 | $93.3M | $60.1M | ||
| Q2 24 | — | $46.8M | ||
| Q1 24 | $84.0M | $45.1M |
净利润BIOXRDI
| Q4 25 | — | $-2.6M | ||
| Q3 25 | $-7.4M | $-4.2M | ||
| Q2 25 | — | $-2.7M | ||
| Q1 25 | $-1.6M | $-4.8M | ||
| Q4 24 | $605.2K | $-2.2M | ||
| Q3 24 | $-6.2M | $-7.0M | ||
| Q2 24 | — | $-12.8M | ||
| Q1 24 | $9.8M | $-13.2M |
毛利率BIOXRDI
| Q4 25 | — | — | ||
| Q3 25 | 46.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 39.4% | — | ||
| Q4 24 | 42.0% | — | ||
| Q3 24 | 40.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 50.8% | — |
营业利润率BIOXRDI
| Q4 25 | — | -1.9% | ||
| Q3 25 | 9.3% | -0.6% | ||
| Q2 25 | — | 4.8% | ||
| Q1 25 | 1.5% | -17.2% | ||
| Q4 24 | 14.5% | 2.6% | ||
| Q3 24 | 2.5% | -0.6% | ||
| Q2 24 | — | -16.4% | ||
| Q1 24 | 15.7% | -16.7% |
净利率BIOXRDI
| Q4 25 | — | -5.1% | ||
| Q3 25 | -9.6% | -8.0% | ||
| Q2 25 | — | -4.4% | ||
| Q1 25 | -2.6% | -11.8% | ||
| Q4 24 | 0.6% | -3.8% | ||
| Q3 24 | -6.6% | -11.7% | ||
| Q2 24 | — | -27.4% | ||
| Q1 24 | 11.6% | -29.4% |
每股收益（稀释后）BIOXRDI
| Q4 25 | — | $-0.11 | ||
| Q3 25 | $-0.12 | $-0.18 | ||
| Q2 25 | — | $-0.12 | ||
| Q1 25 | $-0.02 | $-0.21 | ||
| Q4 24 | $0.00 | $-0.11 | ||
| Q3 24 | $-0.10 | $-0.31 | ||
| Q2 24 | — | $-0.57 | ||
| Q1 24 | $0.14 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $15.5M | $10.5M |
| 总债务越低越好 | — | $185.1M |
| 股东权益账面价值 | $288.3M | $-18.2M |
| 总资产 | $734.9M | $434.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BIOXRDI
| Q4 25 | — | $10.5M | ||
| Q3 25 | $15.5M | $8.1M | ||
| Q2 25 | — | $9.1M | ||
| Q1 25 | $38.5M | $5.9M | ||
| Q4 24 | $29.2M | $12.4M | ||
| Q3 24 | $32.3M | $10.1M | ||
| Q2 24 | — | $9.3M | ||
| Q1 24 | $16.4M | $7.5M |
总债务BIOXRDI
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BIOXRDI
| Q4 25 | — | $-18.2M | ||
| Q3 25 | $288.3M | $-12.1M | ||
| Q2 25 | — | $-7.7M | ||
| Q1 25 | $345.0M | $-8.1M | ||
| Q4 24 | $346.3M | $-4.4M | ||
| Q3 24 | $346.0M | $1.6M | ||
| Q2 24 | — | $6.5M | ||
| Q1 24 | $348.5M | $18.0M |
总资产BIOXRDI
| Q4 25 | — | $434.9M | ||
| Q3 25 | $734.9M | $435.2M | ||
| Q2 25 | — | $438.1M | ||
| Q1 25 | $798.2M | $441.0M | ||
| Q4 24 | $835.2M | $471.0M | ||
| Q3 24 | $827.3M | $495.7M | ||
| Q2 24 | — | $494.9M | ||
| Q1 24 | $836.1M | $494.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $4.3M |
| 自由现金流经营现金流 - 资本支出 | — | $4.1M |
| 自由现金流率自由现金流/营收 | — | 8.2% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-2.9M |
8季度趋势，按日历期对齐
经营现金流BIOXRDI
| Q4 25 | — | $4.3M | ||
| Q3 25 | $14.4M | $295.0K | ||
| Q2 25 | — | $1.6M | ||
| Q1 25 | $23.3M | $-7.7M | ||
| Q4 24 | $-5.4M | $8.0M | ||
| Q3 24 | $5.2M | $1.3M | ||
| Q2 24 | — | $-10.4M | ||
| Q1 24 | $-17.4M | $-2.8M |
自由现金流BIOXRDI
| Q4 25 | — | $4.1M | ||
| Q3 25 | — | $-246.0K | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $-8.0M | ||
| Q4 24 | — | $7.0M | ||
| Q3 24 | — | $-1.1M | ||
| Q2 24 | — | $-10.6M | ||
| Q1 24 | — | $-4.7M |
自由现金流率BIOXRDI
| Q4 25 | — | 8.2% | ||
| Q3 25 | — | -0.5% | ||
| Q2 25 | — | 1.9% | ||
| Q1 25 | — | -19.8% | ||
| Q4 24 | — | 12.0% | ||
| Q3 24 | — | -1.8% | ||
| Q2 24 | — | -22.7% | ||
| Q1 24 | — | -10.4% |
资本支出强度BIOXRDI
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | — | 4.0% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 4.3% |
现金转化率BIOXRDI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -8.85× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.78× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIOX
暂无分部数据
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
